Maze Therapeutics
- Country
- Ownership
- -
- Employees
- 121
- Market Cap
- -
- Introduction
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes Compass platform, which allows to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 28, 2019 and is headquartered in San Francisco, CA.
Clinical Trials
2
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A Phase 2 Study of MZE829 in Adults with APOL1 Kidney Disease
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Maze Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT06830629
- Locations
- 🇺🇸
Apogee Clinical Research, Huntsville, Alabama, United States
🇺🇸Amicis Research Center, Valencia, California, United States
🇺🇸Clinical Research of Brandon, LLC, Brandon, Florida, United States
A Randomized Phase 1 of of MZE001 in Healthy Volunteers
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Maze Therapeutics
- Target Recruit Count
- 121
- Registration Number
- NCT05249621
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
News
Maze Therapeutics Initiates Phase 2 Trial of MZE829 for APOL1 Kidney Disease
• Maze Therapeutics has dosed the first patient in its Phase 2 HORIZON study, evaluating MZE829 for APOL1 kidney disease (AKD). • The HORIZON trial is an open-label, basket design study including AKD patients with varying degrees of proteinuria and diabetic AKD. • The primary endpoint is a 30% or greater reduction in proteinuria, measured by urinary albumin-to-creatinine ratio (uACR) at week 12. • Interim proof-of-concept data from the HORIZON study is expected in the first quarter of 2026, according to Maze Therapeutics.
Atlas Venture Closes $450M Fund XIV, Nuvig, Maze, and Antag Secure Financing for Biotech Innovation
• Atlas Venture closed its fourteenth fund, securing $450 million to invest in and cultivate new biotech startups focused on developing innovative medicines. • Nuvig Therapeutics completed a $161 million Series B financing to advance its lead drug, NVG-2089, into Phase 2 trials for autoimmune diseases like chronic inflammatory demyelinating polyneuropathy (CIDP). • Maze Therapeutics raised $115 million in a Series D round to progress clinical development of its oral APOL1 inhibitor MZE829 for APOL1 kidney disease and SCL6A19 inhibitor MZE782 for chronic kidney disease. • Antag Therapeutics secured €80 million in Series A funding to develop AT-7687, a GIPR antagonist, as a next-generation weight-loss therapy, potentially used alongside incretin therapies.
Maze Therapeutics Secures $115 Million to Advance Kidney Disease Therapies
• Maze Therapeutics has completed a $115 million Series D financing to support the development of precision medicines for renal, cardiovascular, and metabolic diseases. • The funding will advance MZE829, an oral APOL1 inhibitor, into a Phase 2 trial for APOL1 kidney disease (AKD), including focal segmental glomerulosclerosis (FSGS), expected in Q1 2025. • MZE782, an oral SCL6A19 inhibitor, is currently in a Phase 1 trial and is being considered as a treatment for chronic kidney disease (CKD) and phenylketonuria (PKU), with data expected in H2 2025.
Pompe Disease Pipeline Shows Promise with Novel Therapies in Development
• The Pompe disease pipeline is robust, featuring over 20 drugs in development across 15+ companies, targeting novel treatment approaches. • GeneCradle Therapeutics' GC301, a gene therapy, is in Phase I/II trials, showing potential for enzyme replacement therapy discontinuation and motor ability improvement. • Maze Therapeutics' MZE001, an oral glycogen synthase inhibitor, is in Phase I, aiming to reduce glycogen buildup in Pompe disease patients. • Key players like Amicus Therapeutics and Spark Therapeutics are advancing therapies such as Cipaglucosidase alfa and SPK-3006 through clinical trials.
Maze Therapeutics' MZE829 Shows Promise in Phase I Trial for APOL1 Kidney Disease
• Maze Therapeutics' MZE829 demonstrated favorable safety and tolerability in a Phase I trial involving healthy volunteers. • Pharmacokinetic analysis suggests MZE829 is suitable for once-daily oral administration, simplifying dosing for patients. • The trial results support the advancement of MZE829 into a Phase II trial for APOL1 kidney disease (AKD), planned for early 2025. • MZE829, an APOL1 inhibitor, holds potential as a novel therapy for AKD, particularly benefiting individuals of West African descent.
Maze Therapeutics' MZE829 Shows Promise in Phase 1 Trial for APOL1 Kidney Disease
• Maze Therapeutics announced positive Phase 1 results for MZE829, an oral APOL1 inhibitor, in healthy volunteers, showing it was well-tolerated with dose-proportional pharmacokinetics. • The trial supports once-daily dosing of MZE829 and its potential co-administration with standard-of-care medications for APOL1 kidney disease (AKD). • A Phase 2 open-label basket trial is planned for Q1 2025 to assess MZE829's efficacy in AKD patients with varying clinical characteristics and disease severity. • MZE829 targets APOL1, a genetically validated driver of kidney disease, offering a precision medicine approach for individuals of West African ancestry at high risk.
Maze Therapeutics Initiates Phase 1 Trial of MZE782 for Chronic Kidney Disease
• Maze Therapeutics has begun a Phase 1 clinical trial for MZE782, a novel oral small molecule targeting SLC6A19, in healthy volunteers. • MZE782 aims to address the unmet needs of approximately five million CKD patients in the U.S. who do not respond adequately to current treatments. • The trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MZE782, with initial results expected in the second half of 2025. • MZE782 represents a potential first-in-class therapy that could be used alone or in combination with existing standard-of-care treatments for CKD.
Inaxaplin Shows Promise in Addressing APOL1-Mediated Kidney Disease Disparity in Black Americans
• A clinical trial of inaxaplin, a novel drug targeting the APOL1 protein, demonstrated a significant reduction in protein leakage in the urine of patients with serious kidney disease. • The study focused exclusively on African American participants with APOL1 gene variants (G1 and G2) linked to a higher risk of renal failure, addressing a significant racial health disparity. • Vertex Pharmaceuticals is conducting a larger Phase 2/3 trial to investigate inaxaplin's efficacy across multiple kidney disease types in individuals with two APOL1 gene variants. • Insights into APOL1 may also refine kidney transplant policies by using APOL1 genotype instead of race to assess donor kidney viability, potentially increasing the number of available kidneys.
Maze Therapeutics Secures $190 Million to Advance Precision Medicine Programs
• Maze Therapeutics has raised $190 million to support its nine precision medicine programs targeting genetically defined diseases. • The funding will advance clinical trials for MZE001, a treatment for Pompe disease, expected to begin in the first half of 2022. • Maze's Compass platform, designed to accelerate drug discovery through genetic and genomic data analysis, will also be expanded. • The financing will also support programs for chronic kidney disease and amyotrophic lateral sclerosis (ALS).